HORIZON EUROPE
Europeo
Specific Challenge:Innovative solutions for healthcare have the potential to improve patient care in European healthcare setting. Integrated care[1] principles allow care for patients to be better coordinated, and jointly planned by the health and social care professionals across vertically and horizontally relevant preventive and curative services. To respond to changing organisation of care and support the transition of hospital services towards a patient-centred integrated care model, healthcare providers are encouraged to join forces and create demand for such innovations through public joint procurement, serving the triple aim of healthcare: better care experience, better care outcomes, and more efficient care.
Implementation of timely and correct diagnostics for infectious diseases that will speed up the identification of the causative infectious disease pathogens, resistance and drug susceptibility is crucial for tailoring the antimicrobial treatment to ensure appropriate antimicrobial drug use and to reduce unnecessary prescriptions. As innovative rapid diagnostics are significantly more expensive than culture-based diagnostics that are widely used since decade...
ver más
Specific Challenge:Innovative solutions for healthcare have the potential to improve patient care in European healthcare setting. Integrated care[1] principles allow care for patients to be better coordinated, and jointly planned by the health and social care professionals across vertically and horizontally relevant preventive and curative services. To respond to changing organisation of care and support the transition of hospital services towards a patient-centred integrated care model, healthcare providers are encouraged to join forces and create demand for such innovations through public joint procurement, serving the triple aim of healthcare: better care experience, better care outcomes, and more efficient care.
Implementation of timely and correct diagnostics for infectious diseases that will speed up the identification of the causative infectious disease pathogens, resistance and drug susceptibility is crucial for tailoring the antimicrobial treatment to ensure appropriate antimicrobial drug use and to reduce unnecessary prescriptions. As innovative rapid diagnostics are significantly more expensive than culture-based diagnostics that are widely used since decades, the uptake of these new tests in hospitals and especially primary care centres has been limited. To respond to this clinical and public health need and to facilitate the uptake of innovative rapid diagnostics for infectious diseases into healthcare practice, contracting authorities can act together to create demand for such innovations through public joint procurement.
However, before joint innovation procurement can be undertaken, first the cross-border cooperation between interested healthcare procurers must be established to counter fragmentation of delivering innovative solutions in healthcare settings[2].
Scope:The objective of this coordination and support action (CSA) is to create a Europe-wide consortium of healthcare providers and public procurers in the health and social care sector that define together unmet procurement needs to implement innovative solutions in healthcare.
The consortium should prepare future procurement topics to conduct:
A PCP/PPI to implement rapid diagnostic tools for infectious diseases in clinical practise (at least 1 topic). To assure the compatibility and interoperability between infectious disease diagnostics and avoid technological standardisation issues, public health sector procurers that participate in this CSA should also develop specifications that are suitable for Europe-wide deployment of the innovative diagnostics.One or more PCP/PPIs to drive the shift towards health systems reform. Clinicians, patients, public procurers in healthcare systems, health and social care facility managers, and health insurers/payers should work jointly to identify the gaps and needs that will lead to the development of new innovative solutions for patient-centred integrated healthcare. Activities supported by this CSA should include the following aspects:
preparation of innovation procurement calls to be published in topic SC1-BHC-20-2020 of the Work Programme 2018-2020. That topic will follow the specific requirements for innovation procurement PCP/PPI supported by Horizon 2020 grants as set out in General Annex E of the work programme.open market consultation with the industry, including on technical and service readinessanalysis of the suitable testing environmentsanalysis of differences in legal public procurement framework for the participating procurers in health and social care,market analysis and analysis of potential barriers (standardisation, certification, regulatory requirements, intellectual property rights, contracting models, payment schemes)consultations with relevant stakeholders, end-users (consumer organisations, reimbursement bodies) to prepare for a future market uptake of the solutions.
Expected Impact: Improved networking of health and social care providers and public procurers in healthcare systems to identify stakeholders and specifications for a strategy to launch procurement for innovative diagnostics for infectious diseases, and for innovative solutions in integrated care. Optimised procurement strategy for innovative infectious disease diagnostics and for innovative solutions in integrated care. The Commission considers that a proposal requesting an EU contribution between EUR 1.5 and 2 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Cross-cutting Priorities:Open Innovation
[1]Integrated care considers initiatives seeking to improve outcomes of care by overcoming issues of fragmentation through linkage or coordination of services of different providers along the continuum of care
[2]This call topic is complementary but separate from DTH-10-2019-2020 for digital solutions for health and care services
ver menos
Características del consorcio
:
La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Características del Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Características de la financiación
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The thresholds for each criterion in a single stage process will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Coordination and Support Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
Essential information for clinical studies
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The thresholds for each criterion in a single stage process will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Coordination and Support Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
Essential information for clinical studies
6. Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.
Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.
8. Additional documents:
Introduction WP 2018-20
Health, demographic change and well-being WP 2018-20
General annexes to the Work Programme 2018-2020
Legal basis: Horizon 2020 Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme
7. Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in Annex L of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.
Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
Información adicional de la convocatoria
Otras ventajas
Ayudas Similares
| Abierta
| Próximamente
| Abierta